Trial Profile
A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Four Different Doses of Org 50081 in the Treatment of Moderate to Severe Vasomotor Symptoms Associated With the Menopause
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Esmirtazapine (Primary)
- Indications Hot flashes; Postmenopause; Vasomotor symptoms
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Organon
- 07 Jun 2019 This trial has been completed in Spain, according to European Clinical Trials Database.
- 07 Jun 2019 This trial has been completed in Finland, according to European Clinical Trials Database.
- 07 Oct 2009 Additional lead trial centre and sponsor (Schering-Plough) identified as reported by ClinicalTrials.gov.